Intensity Therapeutics Stock
Intensity Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lewis H. Bender
- Employees
- 16
- Market cap
- $9 M
- IPO
- 30/06/2023
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This…
Intensity Therapeutics stock: price history
1D
-0.9%
1W
-7.7%
1M
-12.1%
6M
-36.8%
YTD
-67.3%
1Y
-49.0%
2Y
-95.9%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~38% weaker price swings than usual
Ask the agents about Intensity Therapeutics
Analyst assessment of Intensity Therapeutics
PRICE TARGET LOW
US$7.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 18/08/2026
Intensity Therapeutics stock metrics
P/E
-0.69
P/B
0.98
EV/EBITDA
0.03
RETURN ON EQUITY
-32.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
53.9%
FLOAT SHARES
1,456,282
AVG. DAILY VOLUME (30D)
20,930
Insider transactions (SEC)
Talamo Joseph
Wesolowski John M
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Intensity Therapeutics stock
What does Intensity Therapeutics do?
Intensity Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lewis H. Bender, the company employs around 16 people.
The IPO was on 30/06/2023; the stock trades on NASDAQ under the ticker INTS.
What do analysts say about Intensity Therapeutics stock?
3 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$11.00, ranging from US$7.00 to US$15.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Intensity Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -38% stronger than usual.
Does Intensity Therapeutics pay a dividend?
No, Intensity Therapeutics currently does not pay a dividend.
Which stocks are comparable to Intensity Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Intensity Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Intensity Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.